#2919
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs
Introduction:
Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Pavlakis N
Authors:
Pavlakis N,
Ransom D,
Wyld D,
Sjoquist K,
Asher R,
Keywords:
Lutate,
PRRT,
chemotherapy,
CAPTEM,
NETs,
#2713
The Economic Impact to Patients with Neuroendocrine Tumours
Introduction:
The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Wyld D
Authors:
Wyld D,
Elliott T,
Wakelin K,
Leyden S,
Leyden J,
Keywords:
Financial Toxicity,
Economic impact,
Quality of Life,
NETs,
#2286
A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine
Introduction:
PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
van der Zwan W
Authors:
Van der Zwan W,
Wyld D,
Brabander T,
Teunissen J,
Kam B,
Keywords:
PRRT,
177Lu-DOTATATE,
Capecitabine,
Xeloda,
PFS,
OS,
Toxicity,
GEP-NET,
RCT,
Randomized,
#1425
Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.
Introduction:
Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.
Conference:
13th Annual ENETSConcerence (2016)
Presenting Author:
Authors:
Lucas C,
Goodman S,
Smith J,
Burge M,
Wyld D,
Keywords:
lutetium,
dosimetry,
renal,
gelatin,
somatostatin,